Information Provided By: 
Fly News Breaks for June 28, 2019
ZGNX
Jun 28, 2019 | 04:57 EDT
Mizuho analyst Difei Yang raised her price target for Zogenix to $65 from $58 following the FDA's decision to allow a re-submission of the new drug application for Fintepla. The analyst believes a priority review is highly likely and views the FDA's decision as a positive. She reiterates a Buy rating on Zogenix shares.
News For ZGNX From the Last 2 Days
There are no results for your query ZGNX
